Monitor regulatory milestones (FDA licensure) and closing progress. The estimated >$10M revenue addition provides a concrete near-term catalyst, but deal completion risk remains. A prior 8-K (July 27) suggests this transaction has been in active documentation — further 8-Ks on closing or regulatory steps will be key triggers.
Price Chart
Executive Summary
FOXO Technologies' subsidiary Vector BioSource has entered a definitive agreement to acquire four U.S.-based blood collection centers from Grifols Bio Supplies. The deal, structured as an asset purchase with an upfront cash payment and earnout based on EBITDA targets, is expected to add over $10 million in net revenue in the 12 months post-close. Closing is expected in Q3/Q4 2026 and is subject to FDA licensure and other regulatory approvals.
Key Facts
- Vector BioSource, a FOXO subsidiary, to acquire four U.S. blood collection centers from Grifols Bio Supplies, Inc.
- Estimated net revenue addition of over $10 million in the twelve months following closing
- Transaction structured as asset purchase with upfront cash and potential earnout based on EBITDA targets
- Closing expected in Q3 or Q4 2026, subject to FDA licensure and other regulatory conditions
Financial Impact
Over $10 million in net revenue addition expected in 12 months post-close, subject to closing and regulatory approvals.
Risk Factors
- Failure to obtain FDA licensure or other regulatory authorizations could delay or prevent closing
- Upfront cash payment requires financing — risk if funds are not secured
- Earnout dependent on achieving EBITDA targets; acquired centers may underperform
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-035110 |
| Exhibit: ex99-1.htm | 0001493152-26-035110 |
| Document: 0001493152-26-035110-index-headers.html | 0001493152-26-035110 |
| Document: 0001493152-26-035110-index.html | 0001493152-26-035110 |
| Document: 0001493152-26-035110.txt | 0001493152-26-035110 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 29, 2026 12w ago | 8-K | $0.0922 $0.0922 | · 0.00% | ▼ −5.53% | $0.1000 (+8.46%) |
Jul 27, 2026 13w ago | 8-K | $0.0346 $0.0884 | ▲ +155.49% | ▲ +151.38% | $0.1000 (+189.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers